Brief: Arrowhead Pharmaceuticals Granted Entry In The FDA Star Pilot Program For Plozasiran In Severe Hypertriglyceridemia
07/10/2026 12:33
BRIEF-Arrowhead Pharmaceuticals Granted Entry In The FDA Star Pilot Program For Plozasiran In Severe Hypertriglyceridemia Oct 7 (Reuters) - Arrowhead Pharmaceuticals, Inc. ARWR.O:
ARROWHEAD PHARMACEUTICALS GRANTED ENTRY IN THE FDA STAR PILOT PROGRAM FOR PLOZASIRAN IN SEVERE HYPERTRIGLYCERIDEMIA
ARROWHEAD PHARMACEUTICALS - TO SUBMIT SND A FOR PLOZASIRAN IN SHTG TO FDA BY YEAR-END 2026
Source text: ID:nBw5fBtr8a
Further company coverage: ARWR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers